Denosumab – a new option for solid tumours metastatic to bone

Philip Saylor

Zoledronic acid is a potent bisphosphonate used as the standard therapy for the prevention of skeletal-related events in patients with solid tumours metastatic to bone. Three phase III studies have reported head-to-head comparisons of zoledronic acid with denosumab, an inhibitor of the RANK signaling pathway.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.